Skip to main content
. 2022 Feb 16;139(17):2585–2600. doi: 10.1182/blood.2021014654

Figure 2.

Figure 2

HSCT-treated GC/JAK3 patients have a generalized defect in nasopharyngeal type 2 immunity. (A) Nasopharyngeal levels of type 1 cytokines (interferon [IFN]-γ and tumor necrosis factor [TNF]-α). (B) Nasopharyngeal levels of type 2 cytokines (IL-4, IL-5, and IL-13). (C) Nasopharyngeal levels of type 3 cytokines (IL-17A, IL-17F, and IL-22). (D) Nasopharyngeal levels of IL-33, IL-6, and eosinophil cationic protein (ECP)/RNase 3. (E) Heatmap representation of the mean of the concentration of all nasopharyngeal cytokines in healthy and HSCT-treated SCID patients. Panels A-D: box plots with median ± minimum to maximum. P values were determined with the Kruskal-Wallis test followed by Dunn's posttest for multiple group comparisons; *P < .05, **P < .005, ***P < .001. n.s., not significant.